ProNET — Psychosis Risk Network
ProNET: Psychosis-Risk Outcomes Network
This project follows people at clinical high risk for psychosis and healthy volunteers over time using brain scans, tests, blood/saliva samples, speech measures, and phone data to find signs that predict who may develop psychosis.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11382294 on NIH RePORTER |
What this research studies
If you join, you'll complete a baseline visit and repeated follow-ups over 24 months that include MRI brain scans, EEG, cognitive and symptom tests, genetic and body-fluid samples, speech tasks, and passive smartphone data collection. About 1,040 people at clinical high risk and 260 healthy volunteers across an international network will enroll, with key biomarker measurements taken at two or more timepoints. The study collects data at eight timepoints to map clinical and brain-behavior changes over a treatment-relevant window. Participation involves in-person visits at a ProNET site plus brief remote surveys and phone-based monitoring.
Who could benefit from this research
Good fit: Ideal candidates are people identified as being at clinical high risk for psychosis (for example, experiencing attenuated or brief psychotic symptoms) who can attend study visits and provide biological samples and phone data.
Not a fit: People without risk signs for psychosis, or those unwilling/unable to complete repeated scans, samples, and phone monitoring, are unlikely to get direct benefit from participating.
Why it matters
Potential benefit: If successful, this work could help identify earlier and more reliable signs of who is likely to develop psychosis so care can be targeted sooner.
How similar studies have performed: Prior smaller studies have reported promising candidate biomarkers but results have been inconsistent, so this larger, multi-site network approach is more comprehensive and relatively novel.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Woods, Scott W — Yale University
- Study coordinator: Woods, Scott W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.